Kansal AR - Search Results

1

Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness.

Kansal AR, Sharma M, Bradley-Kennedy C, Clemens A, Monz BU, Peng S, Roskell N, Sorensen SV. Kansal AR, et al. Thromb Haemost. 2012 Oct;108(4):672-82. doi: 10.1160/TH12-06-0388. Epub 2012 Aug 17. Thromb Haemost. 2012. PMID: 22898892

2

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective.

Sorensen SV, Kansal AR, Connolly S, Peng S, Linnehan J, Bradley-Kennedy C, Plumb JM. Sorensen SV, et al. Among authors: kansal ar. Thromb Haemost. 2011 May;105(5):908-19. doi: 10.1160/TH11-02-0089. Epub 2011 Mar 22. Thromb Haemost. 2011. PMID: 21431243

3

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation.

Kansal AR, Sorensen SV, Gani R, Robinson P, Pan F, Plumb JM, Cowie MR. Kansal AR, et al. Heart. 2012 Apr;98(7):573-8. doi: 10.1136/heartjnl-2011-300646. Heart. 2012. PMID: 22422743 Free PMC article. Clinical Trial.

4

Inclusion of compliance and persistence in economic models: past, present and future.

Kadambi A, Leipold RJ, Kansal AR, Sorensen S, Getsios D. Kadambi A, et al. Among authors: kansal ar. Appl Health Econ Health Policy. 2012 Nov 1;10(6):365-79. doi: 10.1007/BF03261872. Appl Health Econ Health Policy. 2012. PMID: 23030640 Review.

5

A comparative analysis of models used to evaluate the cost-effectiveness of dabigatran versus warfarin for the prevention of stroke in atrial fibrillation.

Sorensen SV, Peng S, Monz BU, Bradley-Kennedy C, Kansal AR. Sorensen SV, et al. Among authors: kansal ar. Pharmacoeconomics. 2013 Jul;31(7):589-604. doi: 10.1007/s40273-013-0035-8. Pharmacoeconomics. 2013. PMID: 23615895 Free PMC article.

6

Cost-effectiveness of a FISH assay for the diagnosis of melanoma in the USA.

Kansal AR, Shaul AJ, Stern S, Busam K, Doucet CA, Chalfin DB. Kansal AR, et al. Expert Rev Pharmacoecon Outcomes Res. 2013 Jun;13(3):371-80. doi: 10.1586/erp.13.22. Epub 2013 May 15. Expert Rev Pharmacoecon Outcomes Res. 2013. PMID: 23672374

7

Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation.

Kansal AR, Zheng Y, Pokora T, Sorensen SV. Kansal AR, et al. Best Pract Res Clin Haematol. 2013 Jun;26(2):225-37. doi: 10.1016/j.beha.2013.07.012. Epub 2013 Aug 1. Best Pract Res Clin Haematol. 2013. PMID: 23953910 Review.

8

Modeling hard clinical end-point data in economic analyses.

Kansal AR, Zheng Y, Palencia R, Ruffolo A, Hass B, Sorensen SV. Kansal AR, et al. J Med Econ. 2013 Nov;16(11):1327-43. doi: 10.3111/13696998.2013.838960. Epub 2013 Sep 24. J Med Econ. 2013. PMID: 24032651 Free article. Review.

9

Efficacy and cost-effectiveness of dabigatran etexilate versus warfarin in atrial fibrillation in different age subgroups.

Clemens A, Peng S, Brand S, Brueckmann M, Kansal A, Lim J, Noack H, Sander S, Sorensen S. Clemens A, et al. Am J Cardiol. 2014 Sep 15;114(6):849-55. doi: 10.1016/j.amjcard.2014.06.015. Epub 2014 Jul 2. Am J Cardiol. 2014. PMID: 25103918 Free article.

10

Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.

Zheng Y, Sorensen SV, Gonschior AK, Noack H, Heinrich-Nols J, Sunderland T, Kansal AR. Zheng Y, et al. Among authors: kansal ar. Clin Ther. 2014 Dec 1;36(12):2015-2028.e2. doi: 10.1016/j.clinthera.2014.09.015. Epub 2014 Oct 23. Clin Ther. 2014. PMID: 25438722 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

51 results

Search Page

Filters